MINI FUTURE LONG - UCB Stock

R7RHB

NLBNPNL1ZM38

Market Closed - Euronext Paris 12:30:00 2024-06-28 EDT
16.06 ^EUR	+1.13%

Current month	+14.87%
1 month	+16.20%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)	06-28	PU
UCB : Financial Reporting Document	06-26	PU
UCB : Financial Reporting Document	06-26	PU
UCB : epilepsy drug BRIVIACT(brivaracetam) approved in Japan for treatment of focal onset seizures	06-26	PU

More news

Quotes 5-day view

Date	Price	Change
24-06-28	16.06	+1.13%
24-06-27	15.88	+0.95%
24-06-26	15.74	+0.38%
24-06-25	15.68	-2.43%
24-06-24	16.06	-0.37%

Real-time Euronext Paris

Last update June 28, 2024 at 12:30 pm

More quotes

Static data

Product type	Knock-Out with Stop Loss
Buy / Sell	CALL
Underlying	UCB
Issuer	BNP Paribas
	R7RHB
ISIN	NLBNPNL1ZM38
Date issued	2022-08-04
Strike	58.98 €
Maturity	Unlimited
Parity	5 : 1
Emission price	3.66 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	16.2 €
Lowest since issue	1.56 €

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

138.7 EUR

Average target price

139.7 EUR

Spread / Average Target

+0.72%

Consensus